Arbutus Biopharma (ABUS) FCF Margin (2013 - 2026)

Arbutus Biopharma has disclosed FCF Margin across 14 years of filings, most recently posting 4.53% for Q1 2026.

• FCF Margin for Q1 2026 came in at 4.53%, up 75460.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.95% (up 90401.0% YoY), and the FY2025 annual result was 281.45%, up 77238.0% from the prior year.
• FCF Margin came in at 4.53% for Q1 2026 at Arbutus Biopharma, up from 445.29% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 163.29% in Q1 2022 to a low of 1548.62% in Q3 2024.
• The 5-year median for FCF Margin is 445.29% (2025), against an average of 556.75%.
• Across the five-year window, FCF Margin soared 101422 bps in 2022 and plunged 108026 bps in 2024, its largest moves.
• Arbutus Biopharma's FCF Margin stood at 274.2% in 2022, then tumbled by 194 bps to 806.15% in 2023, then advanced by 18 bps to 660.8% in 2024, then jumped by 33 bps to 445.29% in 2025, then soared by 99 bps to 4.53% in 2026.
• The last three FCF Margin figures came in at 4.53% (Q1 2026), 445.29% (Q4 2025), and 1099.62% (Q3 2025), per Business Quant data.